New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 22, 2016 – The FDA announced the removal of the indication for secondary bacterial infection of acute bronchitis (SBIAB) from the Cefzil (cefprozil) and Ceftin (cefuroxime axetil) drug labels.
Download PDF
Return to publications
